Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Sinovac vaccine shows 67% efficacy against symptomatic Covid-19 in Chilean trial – US CDC to review J&J vaccine pause on Friday

19 Apr 2021 (Last Updated April 19th, 2021 10:17)

Chinese pharma company Sinovac’s Covid-19 vaccine CoronaVac has demonstrated 67% efficacy against symptomatic Covid-19 infections in a large real-world study in Chile. The vaccine showed effectiveness against admission to ICU, hospitalisation and death, with respective efficacy rates of 89%, 85% and 80%, according to a Chilean government report.

A US Centers for Disease Prevention (CDC) advisory panel is scheduled to meet on Friday 23 April to decide whether to continue the pause of J&J’s Covid-19 vaccine rollout. The panel will examine additional cases that have come up and assess risks arising from its administration. The use of the J&J vaccine was suspended following six cases of unusual brain blood clots reported in women out of approximately seven million people who received the one-shot vaccine in the US.

Eli Lilly has requested that the US Food and Drug Administration (FDA) revoke the emergency use authorisation (EUA) for bamlanivimab (LY-CoV555) 700mg as a Covid-19 monotherapy. The request comes as Lilly transitions to only supplying bamlanivimab and etesevimab in combination to treat Covid-19 in the country. Lilly’s request was in view of the surge in Covid-19 variants across the US and not related to any safety concerns.